The role of hypolipemic drugs today;Uloga i mjesto hipolipemika danas

Medicus

Volumn 11, Issue 1, 2002, Pages 37-47

  Reiner, Željko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Acute coronary syndromes; Coronary heart disease; Diabetes; Fibrates; Statins

Indexed keywords

BEZAFIBRATE; CERIVASTATIN; CLARITHROMYCIN; COLESTIPOL; COLESTYRAMINE; COMPACTIN; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; PRAVASTATIN; PROBUCOL; PROTEINASE INHIBITOR; RITONAVIR; SIMVASTATIN; STATEX; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR PERFORMANCE; CHOLESTEROL BLOOD LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FLATULENCE; HEART DEATH; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIMARY PREVENTION; PUBLICATION; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036970128     PISSN: 1330013X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. WOOD D, BACKER GD, FAERGEMAN O, GRAHAM I, MANCIA G, PYORALA K. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998; 19:1434-503.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, the Scandinavian Survival Study. Lancet 1994; 344:1383-9.
3. SACKS FM, PFEFFER MA, MOYE LA. et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335:1001-9.
4. The Long-Term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-57.
5. SHEPHERD J, COBBE SM, FORD I. et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333:1301-7.
6. DOWNS JR, CLEARFIELD M, WEIS S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFACPS/TexCAPS. JAMA 1998; 279:1615-22.
7. COLLINS R, PETO R, ARMITAGE J. The MRC/BHF heart protection study: preliminary results. Int J Clin Pract 2002; 56(1):53-6.
8. HAY JW, YU WM, ASHRAF T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. PharmacoEconomics 1999; 15:47-74.
9. PICKIN DM, McCABE CJ, RAMSAY LE, PAYNE N, HAQ IU, YEO WW, JACKSON PR. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999; 82:325-32.
10. RECKLESS JPD. Cost-effectiveness of statins. Curr Opin Lipidol 2000; 11:351-6.
11. GROVER SA, COUPAL L, ZOWALL H, ALEXANDER CM, WEISS TW, GOMES DRJ. How cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease? Diabetes Care 2001; 24: 45:50.
12. ARONOW HD, TOPOL EJ, ROE MT et al. Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2000; 357:1063-8.
13. STENESTRANS U, WALLENTIN L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285:430-36.
14. FOODY JAM, NISSEN SE. Effectiveness of statins in acute coronary syndromes. Am J Cardiol 2001; 88 (Suppl):31F-35F.
15. BYINGTON B, DAVIS BR, PLAHN JF et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 103:387.
16. AVIRAM M, DANKNER G, COGAN U, HOCHGRAF E, BROOK JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992; 43-229-35.
17. REINER Ž. Oksidacija lipoproteina - ključno zbivanje u razvoju ateroskleroze. Lipidi 1995; 5:13-7.
18. BERNINI F, SCURATI N, BONFADINI G, FUMAGALLI R. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscl Thromb Vasc Biol 1995; 15:1352-8.
19. HRBOTICKY N, DRAUDE G, HAPFELMEIER G, LORENZ R, WEBER PC. Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during early stage of differentiation into macrophages. Arterioscl Thromb Vasc Biol 1999; 19:1267-75.
20. O'DRISCOLL G, GREEN D, TAYLER RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95:1126-31.
21. HERNANDEZ-PERERA O, PEREZ-SALA D, NAVARROANTOLIN J, SANCHEZ-PASCUALA R, HERNANDEZ G, DIAZ C. et al. Effects of the 3-hydroxy-3-methylglutarylCoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin 1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101:2711-9.
22. KAESEMEYER WH, CALDWER RB, HUANG JZ, CALDWELL RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33:234-41.
23. NEGREE-AMINOU P, VAN VLIET AK, van ERCK M et al. Inhibiton of proliferation of human smooth muscle cells by various HMG-COA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1334:250-68.
24. REINER Ž, TEDESCHI-REINER E. Novije spoznaje o patofiziologiji ateroskleroze. Liječ Vjesn 2001; 123:26-31.
25. BELLOSTA S, VIA D, CANAVESI M, PFISTER P, FUMAGALLI R, PAOLETTI R et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18:1671-8.
26. STRANDBERG TE, VANHANEN H,M TIKKANEN MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353:118-9.
27. CRISBY M, NORDIN-FREDRIKSSON G, SHAH PK, YANO J, ZHU J, NILLSON J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103:926.
28. OSAMAH H, MIRA R, SORINA S, SHLOMO K, MICHAEL A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997; 44:77-83.
29. MEADE TW, RUDDOCK V, STIRLING Y, CHAKRABARTI R, MILLER GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-9.
30. ROSENSON RS, TANGENEY CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998; 279:1643-50.
31. SZCZEKLIK A, MUSIAL J, UNDAS A, GAJEWSKI P, GORA P, SWADZBA J. et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33:1286-93.
32. KOPPENSTEINER R, MINAR E, EHRINGER H. Effect of lovastatin on hemorrheology in type II hyperlipoproteinemia. Atherosclerosis 1990; 83:53-8.
33. PINTARIĆ I, ETEROVIĆ D, TOCILJ J, REINER Ž, LUŠIĆ I. Effect of simvastatin on micropulmonary red cell mass in patients with hyperlipoproteinemia. Atherosclerosis 2001; 154: 493-6.
34. FISHER JE, ROGERS MJ, HALASY JM, LUCKMAN SP, HUGHES DE, MASARACHIA PJ et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96:133-8.
35. MUNDY G, GARRETT R, HARRIS S. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286:1946-48.
36. MEIER CR, SCHLIENGER RG, KRAENZLIN ME, SCHLEGEL B, JICK H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283:3205-10.
37. WANG PS, SOLOMON DH, MOGUN H, AVORN J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283:3211-6.
38. CHAN KA, ANDRADE SE, BOLES M et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fractures among older women. Lancet 2000; 355:2185-8.
39. WOLOZIN B, KELLMAN W, ROUSSEAU P, CELESIA GG, SIEGEL G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57:1439.
40. KAESEMEYER WH, CALDWELL RB, HUANG J, CALDWELL RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33:234.
41. BULT H, HERMAN AG. Antiatherosclerotic activity of drugs in relation to nitric oxide function. J Pharmacol 1999; 375:157.
42. FASSBENDER K, SIMONS M et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98:5371-3.
43. WAUGHAN CJ, CELANTY N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 2000; 31:989.
44. SPARKS DL, MARTIN TA, GROSS DR, HUNSAKER JC. Link between heart disease, cholesterol and Alzheimer's disease: a review. Microsc Res Tech 2000; 50:287-90.
45. MALTESE WA. 3-Hydroxy-3-methylgrutaryl coenzyme A reductase in human brain tumors. Neurology 1983; 33:1294-9.
46. SIPERSTEIN MD, GYDE AM, MORRIS HP. Loss of feedback control of hydroxymethylglutaryl coenzyme A reductase in hepatomas. Proc Natl Acad Sci USA 1971; 68:315-7.
47. SOMA MR, PAGLIARINI P, BUTTI G, PAOLETTI R, PAOLETTI P, FUMAGALLI R. Simvastatin, an inhibitor of cholesterol biosynthesis, shows synergistic effect with N,N′-Bis (2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. Cancer Res 1992; 52:4348-5355.
48. BENNIS F, FAVRE G, LE GAILLARD F, SOULA G. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int Cancer 1993; 55:640-5.
49. KILUCHI T, NAGATY Y, ABE T. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J Neurooncol 1997; 34:233-9.
50. SCHMIDT F, GROSCURTH P, KERMER M, DICHGANS J, WELLER M. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. Acta Neuropathol 2001; 101(3):217-24.
51. WACHTERSHAUSER A, AKOGLU B, STEIN J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001; 22(7):1061:7.
52. KAWATA S, YAMASAKI E, NAGASE T. et al. Effects of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Brit J Cancer 2001; 84(7):886-91.
53. DIMITROULAKOS J, THAI S, WASFY GH, HEDLEY DW, MINDEN MD, PENN LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leukemia & Lymphoma 2000; 40(1-2):167-78.
54. XIA Z, TAN MM, WONG WW, DIMITROULAKOS J, MINDEN MD, PENN LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001; 15(9):1398-407.
55. LISHNER M, BAR-SEF A, ELIS A, FABIAN I. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Invest Med 2001; 49(4):319-24.
56. PEDERSEN TR, BERG K, COOK TJ et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 14:156:2085-92.
57. MITCHEL YB. The long-term tolerability profile of lovastatin and simvastatin. Atherosclerosis 1991; 97 (Suppl): S33-S39.
58. GRUER PJK, VEGA JM, MERCURI MF et al. Concomitant of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84:811-5.
59. DAVIDSON MH, STEIN EA, HUNNINGHAKE D et al. The eficacy and safety of simvastatin 80 mg: pooled results from worldwide clinical studies. Atherosclerosis 1999; 144 (Suppl 1): 30.
60. Anonymous. Rhabdomyolysis seen with simvastatin 160 mg. Reactions 1997; 653:2.
61. BLUM CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73:3D-11D.
62. PEDERSEN TR, TOBERT JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reppraisal. Drug Saf 1996; 11:11-24.
63. BACKMAN JT, KYRKLUND C, KIVISTO KT, WANG JS, NEUVONEN PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68:122:9.
64. SHEPHERD J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16:5-13.
65. HOLDAAS H, HARTMANN A, STENSTROM J, DAHL KJ, BORGE M, PFISTER P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76:102A-106A.
66. BITTAR AE, RETCLIFFE PJ, RICHARDSON AJ, RAINE AEG, JONES L, YUDKIN PL, CARTER R, MANN JJ, MORIS PJ. The prevalence of hyperlipidemia in renal transplant recipients: associations with immunosuppressive and antihypertensive therapy. Transplantation 1990; 50: 987-92.
67. LILJA JJ, KIVISTO KT, NEUVONEN PJ. Grapefruit juicesimvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 63:477-83.
68. HOKANSON JE, AUSTIN MA. Plasma triglyceride level is a risk factor to cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. Cardiovasc Risk 1996; 3:213-9.
69. JEPPESEN J, HEIN HO, SUADICANI P, GYNTELBERG F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97:1029-1036.
70. FRICK MH, ELO O, HAAPE K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317:1237-45.
71. RUBINS HB, ROBINS SJ, COLLINS D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410-8.
72. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102:21-7.
73. BUCHER HC, GRIFFITH LE, GUYATT GH. Systemic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19:187-95.